Arcus Biosciences (NYSE:RCUS) CEO Terry Rosen Sells 25,744 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) CEO Terry Rosen sold 25,744 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $22.16, for a total value of $570,487.04. Following the sale, the chief executive officer owned 2,194,809 shares in the company, valued at $48,636,967.44. The trade was a 1.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Arcus Biosciences Price Performance

RCUS opened at $22.02 on Friday. The stock has a market capitalization of $2.38 billion, a P/E ratio of -6.40 and a beta of 0.75. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22. Arcus Biosciences, Inc. has a 12-month low of $6.50 and a 12-month high of $26.40. The stock has a 50-day moving average price of $20.96 and a 200-day moving average price of $14.04.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. During the same quarter in the previous year, the company posted ($1.00) EPS. Arcus Biosciences’s quarterly revenue was down 45.8% compared to the same quarter last year. Equities analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arcus Biosciences

Large investors have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. increased its stake in shares of Arcus Biosciences by 39.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,120,062 shares of the company’s stock valued at $15,233,000 after buying an additional 314,757 shares during the period. Vestal Point Capital LP purchased a new stake in Arcus Biosciences in the third quarter worth $3,400,000. Public Employees Retirement System of Ohio bought a new stake in Arcus Biosciences in the third quarter valued at $299,000. Parkman Healthcare Partners LLC boosted its holdings in Arcus Biosciences by 8.9% in the third quarter. Parkman Healthcare Partners LLC now owns 652,680 shares of the company’s stock valued at $8,876,000 after acquiring an additional 53,070 shares in the last quarter. Finally, Decheng Capital LLC increased its position in Arcus Biosciences by 242.3% during the 3rd quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock valued at $7,447,000 after purchasing an additional 387,609 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RCUS. Citigroup restated a “buy” rating on shares of Arcus Biosciences in a research report on Friday, December 12th. Bank of America increased their target price on Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a report on Friday, November 28th. HC Wainwright raised their price target on Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Truist Financial set a $30.00 price objective on Arcus Biosciences in a research report on Friday, December 12th. Finally, UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research note on Monday. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.89.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.